StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Up 5.3 %

Shares of TRVN opened at $3.94 on Friday. Trevena has a 52-week low of $3.35 and a 52-week high of $19.23. The stock has a market cap of $3.35 million, a PE ratio of -1.47 and a beta of 1.03. The firm’s fifty day moving average is $3.15 and its two-hundred day moving average is $1.35.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.36. The business had revenue of $0.33 million for the quarter. As a group, research analysts anticipate that Trevena will post -32.25 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC purchased a new stake in Trevena, Inc. (NASDAQ:TRVN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.56% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.